nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.06.2012 | NON-THEMATIC REVIEW

Cooperate concept of metastasis: site-specific requirement of activated differentiation and dynamic deterioration

verfasst von: C. Wilmanns, S. Steinhauer, J. Großmann, A. Schmitt-Gräff, G. Ruf

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1-2/2012

Einloggen, um Zugang zu erhalten

Abstract

Cancer metastasis results from positive and negative cellular events such as constitutive activation of oncogenes (cOA) or genetic losses (GL) being modulated by downstream signals of epithelial–mesenchymal or mesenchymal–epithelial transition, thus constituting master programs of metastatic phenotype and site specificity. To address the complex nature of these programs, we introduced clinical and phenotypic markers like tumor size, grade, cellular shape, or expression of E-cadherin in 27 colon cancer (CC) patients (cOA and GL), and 41 patients with gastrointestinal stromal tumors (GIST, cOA) to produce scores of cOA and GL. Scores of cOA were highest in case of hepatic and lower in case of an isolated peritoneal spread (GIST), or (CC) of both, cOA and GL, highest in case of a combined hepatic and peritoneal spread and lower in case of an isolated peritoneal spread; but in case of an isolated hepatic spread, scores of cOA were high and low of GL. This indicates a differential contribution of cellular dissociation and recognition in site-specific metastasis, of cOA predominantly in production of hepatic and in the case of GL of serosal spread.

Poste, G., & Fidler, I. J. (1980). The pathogenesis of cancer metastasis. Nature, 283, 139–146.PubMedCrossRef

Fearon, E. R., & Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell, 61, 759–767.PubMedCrossRef

Fidler, I. J., & Kripke, M. L. (1977). Metastasis results from preexisting variant cells within a malignant tumor. Science, 197, 893–895.PubMedCrossRef

Fidler, I. J., & Poste, G. (2008). The “seed and soil” hypothesis revisited. The Lancet Oncology, 9, 808.PubMedCrossRef

Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003). A molecular signature of metastasis in primary solid tumors. Nature Genetics, 33, 49–54.PubMedCrossRef

Landemaine, T., Jackson, A., Bellahcène, A., Rucci, N., Sin, S., Abad, B. M., et al. (2008). A six-gene signature predicting breast cancer lung metastasis. Cancer Research, 68, 6092–6099.PubMedCrossRef

Staroselsky, A. H., Pathak, S., Chernajovsky, Y., Tucker, S. L., & Fidler, I. J. (1991). Predominance of the metastatic phenotype in somatic cell hybrids of the K-1735 murine melanoma. Cancer Research, 51, 6292–6298.PubMed

Tischoff, I., & Tannapfel, A. (2007). Pathologic and anatomic evidence of peritoneal metastases. Chirurg, 78, 1085–1090.PubMedCrossRef

Finkelstein, S. D., Sayegh, R., Christensen, S., & Swalsky, P. A. (1993). Genotypic classification of colorectal adenocarcinoma. Cancer, 71, 3827–3838.PubMedCrossRef

10.

Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., et al. (2010). Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. PNAS, 107, 246–251.PubMedCrossRef

11.

Lee, K. E., Lee, H.-J., Kim, Y. H., Yu, H. J., Yang, H.-K., Kim, W.-H., et al. (2003). Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Japanese Journal of Clinical Oncology, 33, 173–179.PubMedCrossRef

12.

Guilford, P., Hopkins, J., Harraway, J., McLeod, M., McLeod, N., Harawira, P., et al. (1998). E-cadherin germline mutations in familial gastric cancer. Nature, 392, 402–405.PubMedCrossRef

13.

Richards, F. M., McKee, S. A., Rajpar, M. H., Cole, T. R., Evans, D. G., Jankowski, J. A., et al. (1999). Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Human Molecular Genetics, 8, 607–610.PubMedCrossRef

14.

Sadahiro, S., Suzuki, T., Maeda, Y., Tanaka, A., Makuuchi, H., Kamijo, A., et al. (2009). Prognostic factors in patients with synchronous peritoneal carcinomatosis (PC) caused by a primary cancer of the colon. Journal of Gastrointestinal Surgery, 13, 1593–1598.PubMedCrossRef

15.

Kowalski, P. J., Rubin, M. A., & Kleer, C. G. (2003). E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Research, 5, R217–R222.PubMedCrossRef

16.

Moll, R., Mitze, M., Frixen, U. H., & Birchmeier, W. (1993). Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. American Journal of Pathology, 143, 1731–1742.PubMed

17.

Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., et al. (2008). Wild-type Kras is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26, 1626–1634.PubMedCrossRef

18.

Rubin, B. P., Singer, S., Tsao, C., Duensing, A., Lux, M. L., Ruiz, R., et al. (2001). KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Research, 61, 8118–8121.PubMed

19.

Wu, M., Pastor-Pareja, J. C., & Xu, T. (2010). Interaction between Ras ^V12and scribbled clones induces tumour growth and invasion. Nature, 463, 545–548.PubMedCrossRef

20.

Eder, M. (1984). Metastasis, facts and problems in human pathology. Verhandlungen der Deutschen Gesellschaft für Pathologie, 68, 1–11.

21.

Acs, G., Lawton, T. J., Rebbeck, T. R., LiVolsi, V. A., & Zhang, P. J. (2001). Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. American Journal of Clinical Pathology, 115, 85–98.PubMedCrossRef

22.

Singer, S., Rubin, B. P., Lux, M. L., Chen, C.-J., Demetri, G. D., Fletcher, C. D. M., et al. (2002). Prognostic value of kit mutation type, mitotic activity, and histologic subtype in Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 20, 3898–3905.PubMedCrossRef

23.

Wilmanns, C., Eggstein, S., & Ruf, G. (2007). Score prediction of metastatic risk in gastrointestinal stromal tumours (GIST). Zentralblatt für Chirurgie, 132, 509–514.PubMedCrossRef

24.

Wilmanns, C., Steinhauer, S., Grossmann, J., & Ruf, G. (2009). Site-dependent differences in clinical, pathohistological, and molecular parameters in metastatic colon cancer. International Journal of Biological Sciences, 5, 458–465.PubMedCrossRef

25.

Nordlinger, B., Guiguet, M., Vaillant, J.-C., Balladur, P., Boudjeme, K., Bachallier, P., et al. (1996). Surgical resection of colorectal carcinoma metastases to the liver. Cancer, 77, 1254–1262.PubMedCrossRef

26.

Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999). Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Annals of Surgery, 230, 309–321.PubMedCrossRef

27.

Lennon, A. M., Mulcahy, H. E., Hyland, J. M. P., Lowry, C., White, A., Fennelly, D., et al. (2003). Peritoneal involvement in stage II colon cancer. American Journal of Clinical Pathology, 119, 108–113.PubMedCrossRef

28.

Guerrero, S., Casanova, I., Farré, L., Mazo, A., Capellà, G., & Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Research, 60, 6750–6756.PubMed

29.

Jou, T.-S., & Nelson, W. J. (1998). Effects of regulated expression of mutant rhoA and rac1 small GTPases on the development of epithelial (MDCK) cell polarity. The Journal of Cell Biology, 142, 85–100.PubMedCrossRef

30.

Christofori, G., & Semb, H. (1999). The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends in Biochemical Sciences, 24, 73–76.PubMedCrossRef

31.

Franquemont, D. W. (1995). Differentiation and risk assessment of gastrointestinal stromal tumors. American Journal of Clinical Pathology, 103, 41–47.PubMed

32.

Carro, M. S., Lim, W. K., Alvarez, M. J., Bollo, R. J., Zhao, X., Snyder, E. Y., et al. (2010). The transcriptional network for mesenchymal transformation of brain tumours. Nature, 463, 318–325.PubMedCrossRef

33.

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science, 314, 268–274.PubMedCrossRef

34.

Pratt, C. H., Vadigepalli, R., Chakravarthula, P., Gonye, G. E., Philp, N. J., & Grunwald, G. B. (2008). Transcriptional regulatory network analysis during epithelial-mesenchymal transformation of retinal pigment epithelium. Molecular Vision, 14, 1414–1428.PubMed

35.

Baugher, P. J., Krishnamoorthy, L., Price, J. E., & Dharmawardhane, S. F. (2005). Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells. Breast Cancer Research, 7, R965–R974.PubMedCrossRef

36.

Hall, A. (1998). Rho GTPases and the actin cytoskeleton. Science, 279, 509–514.PubMedCrossRef

37.

Smith, K. J., Levy, D. B., Maupin, P., Pollard, T. D., Vogelstein, B., & Kinzler, K. W. (1994). Wild-type but not mutant APC associates with the microtubule cytoskeleton. Cancer Research, 54, 3672–3675.PubMed

38.

Munemitsu, S., Souza, B., Müller, O., Albert, I., Rubinfeld, B., & Polakis, P. (1994). The APC gene product associates with microtubules in vivo and promotes their assembly in vitro. Cancer Research, 54, 3676–3681.PubMed

39.

Safina, A. F., Varga, A. E., Bianchi, A., Zheng, Q., Kunnev, D., Liang, P., et al. (2009). Ras alters epithelial–mesenchymal transition in response to TGFβ by reducing actin fibers and cell-matrix adhesion. Cell Cycle, 8, 284–298.PubMedCrossRef

40.

Scaltriti, M., & Baselga, J. (2006). The epidermal growth factor receptor pathway: a model for targeted therapy. Clinical Cancer Research, 12, 5268–5272.PubMedCrossRef

41.

August, D. A., Ottow, R. T., & Sugerbaker, P. H. (1984). Clinical perspective of human colorectal cancer metastasis. Cancer and Metastasis Reviews, 3, 303–324.PubMedCrossRef

42.

Loupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D., et al. (2009). PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Journal of Clinical Oncology, 27, 2622–2629.PubMedCrossRef

43.

Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., et al. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science, 244, 217–221.PubMedCrossRef

44.

Anthony, T., George, R., Rodriguez-Bigas, M., & Petrelli, N. J. (1996). Primary signet-ring cell carcinoma of the colon and rectum. Annals of Surgical Oncology, 3, 344–348.PubMedCrossRef

45.

Kern, S. E., Fearon, E. R., Tersmette, K. W. F., Enterline, J. P., Leppert, M., Nakamura, Y., et al. (1989). Allelic loss in colorectal carcinoma. Journal of the American Medical Association, 261, 3099–3103.PubMedCrossRef

46.

Goi, T., Yamaguchi, A., Nakagawara, G., Urano, T., Shiku, H., & Furukawa, K. (1998). Reduced expression of deleted colorectal carcinoma (DCC) protein in established colon cancers. British Journal of Cancer, 77, 466–471.PubMedCrossRef

47.

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417, 949–954.PubMedCrossRef

48.

Artale, S., Sartore-Bianchi, A., Veronese, S. M., Gambi, V., Sarnataro, C. S., Cambacorta, M., et al. (2008). Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. Journal of Clinical Oncology, 26, 4217–4219.PubMedCrossRef

49.

Grille, S. J., Bellacosa, A., Upson, J., Klein-Szanto, A. J., van Roy, F., Lee-Kwon, W., et al. (2003). The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Research, 63, 2172–2178.PubMed

50.

Zeisberg, M., Shah, A. A., & Kalluri, R. (2005). Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. Journal of Biological Chemistry, 280, 8094–8100.PubMedCrossRef

51.

Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., et al. (2005). Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell, 7, 561–573.PubMedCrossRef

52.

Ogino, S., Nosho, K., Kirkner, G. J., Shima, K., Irahara, N., Kure, S., et al. (2009). PIK3CA mutation is associated with poor prognosis among patiens with curatively resected colon cancer. Journal of Clinical Oncology, 27, 1477–1484.PubMedCrossRef

53.

Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y.-M., et al. (2009). PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Research, 69, 4286–4293.PubMedCrossRef

54.

Sanders, K. M., & Ward, S. M. (2006). Interstitial cells of Cajal: a new perspective on smooth muscle function. Journal of Physiology, 576, 721–726.PubMedCrossRef

55.

Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., et al. (2002). Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathology, 33, 459–465.PubMedCrossRef

56.

Yarden, Y., Escobedo, J. A., Kuang, W.-J., Yang-Feng, T. L., Daniel, T. O., Tremble, P. M., et al. (1986). Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature, 323, 226–232.PubMedCrossRef

57.

DeMatteo, R. P., Heinrich, M. C., El-Rifai, W. M., & Demetri, G. (2002). Clinical management of gastrointestinal stromal tumors: before and after STI-571. Human Pathology, 33, 466–477.PubMedCrossRef

58.

Sattler, M., Salgia, R., Shrikhande, G., Verma, S., Pisick, E., Prasad, K. V. S., et al. (1997). Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120^CBL. Journal of Biological Chemistry, 272, 10248–10253.PubMedCrossRef

59.

Yang, J., Du, X., Lazar, A. J. F., Pollock, R., Hunt, K., Chen, K., et al. (2008). Genetic aberrations of gastrointestinal stromal tumors. Cancer, 113, 1532–1543.PubMedCrossRef

60.

Agaimy, A., Pelz, A.-F., Corless, C. L., Wünsch, P. H., Heinrich, M. C., Hofstaedter, F., et al. (2007). Epitheloid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization. Oncology Reports, 18, 9–15.PubMed

61.

Sakamoto, K., Sakurai, S., Kanda, T., Sakuma, Y., Hishima, T., Hironaka, M., et al. (2010). Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment. Cancer Science, 101, 1270–1278.PubMedCrossRef

62.

Shimoyama, Y., Hirohashi, S., Hirano, S., Noguchi, M., Shimosato, Y., Takeichi, M., et al. (1989). Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Research, 49, 2128–2133.PubMed

63.

Berndorff, D., Gessner, R., Kreft, B., Schnoy, N., Lajous-Petter, A.-M., Loch, N., et al. (1994). Liver-intestine cadherin: molecular cloning and characterization of a novel Ca²⁺-dependent cell adhesion molecule expressed in liver and intestine. The Journal of Cell Biology, 125, 1353–1369.PubMedCrossRef

64.

Becker, K.-F., Atkinson, M. J., Reich, U., Becker, I., Nekarda, H., Siewert, J. R., et al. (1994). E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Research, 54, 3845–3852.PubMed

65.

Tamura, G., Yin, J., Wang, S., Fleisher, A. S., Zou, T., Abraham, J. M., et al. (2000). E-cadherin gene promoter hypermethylation in primary human gastric carcinomas. Journal of the National Cancer Institute, 92, 569–573.PubMedCrossRef

66.

Mayer, B., Johnson, J. P., Leitl, F., Jauch, K. W., Heiss, M. M., Schildberg, F. W., et al. (1993). E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Research, 53, 1690–1695.PubMed

67.

Steeg, P. S., Horak, C. E., & Miller, K. D. (2008). Clinical-translational approaches to the nm23-H1 metastasis suppressor. Clinical Cancer Research, 14, 5006–5012.PubMedCrossRef

68.

Douma, S., van Laar, T., Zevenhoven, J., Meuwissen, R., van Garderen, E., & Peeper, D. S. (2004). Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature, 430, 1034–1040.PubMedCrossRef

69.

Yu, Y., Zhang, S., Wang, X., Yang, Z., & Ou, G. (2010). Overexpression of TrkB promotes the progression of colon cancer. APMIS, 118, 188–195.PubMedCrossRef

70.

Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial–mesenchymal transition. The Journal of Clinical Investigation, 119, 1420–1428.PubMedCrossRef

71.

Bissell, M. J., Radisky, D. C., Rizki, A., Weaver, V. M., & Peterson, O. W. (2002). The organizing principle: microenvironmental influences in the normal and malignang breast. Differentiation, 70, 537–546.PubMedCrossRef

Titel: Cooperate concept of metastasis: site-specific requirement of activated differentiation and dynamic deterioration
verfasst von: C. Wilmanns
S. Steinhauer
J. Großmann
A. Schmitt-Gräff
G. Ruf
Publikationsdatum: 01.06.2012
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1-2/2012
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-012-9350-3

Springer Medizin

Cooperate concept of metastasis: site-specific requirement of activated differentiation and dynamic deterioration

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1-2/2012

Translation initiation in colorectal cancer

Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: a review of mechanisms

Role of the ubiquitin ligase Fbw7 in cancer progression

BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype

Positive lymph nodes do not metastasize

The genetic/metabolic transformation concept of carcinogenesis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie